Добірка наукової літератури з теми "Birinapant"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Birinapant".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Birinapant"
Fetterly, Gerald J., Biao Liu, Neil N. Senzer, Ravi K. Amaravadi, Russell J. Schilder, Lainie P. Martin, Patricia LoRusso, et al. "Clinical pharmacokinetics of the Smac-mimetic birinapant (TL32711) as a single agent and in combination with multiple chemotherapy regimens." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 3029. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.3029.
Повний текст джерелаNoonan, Anne M., Amanda Cousins, David Anderson, Kristen P. Zeligs, Kristen Bunch, Lidia Hernandez, Yusuke Shibuya, et al. "Matrix Drug Screen Identifies Synergistic Drug Combinations to Augment SMAC Mimetic Activity in Ovarian Cancer." Cancers 12, no. 12 (December 15, 2020): 3784. http://dx.doi.org/10.3390/cancers12123784.
Повний текст джерелаCarter, Bing Z., Po Yee Mak, Duncan H. Mak, Vivian Ruvolo, Rodrigo Jacamo, Steven M. Kornblau, and Michael Andreeff. "Apoptosis Repressor with Caspase Recruitment Domain Is Regulated by the cIAP1-NIK Axis and Confers Resistance to SMAC Mimetic Birinapant-Induced Cell Death in AML." Blood 120, no. 21 (November 16, 2012): 534. http://dx.doi.org/10.1182/blood.v120.21.534.534.
Повний текст джерелаSmith, Malcolm A., Hernan Carol, Kathryn Evans, Jennifer Richmond, Min Kang, C. Patrick Reynolds, Srinivas Chunduru та ін. "Birinapant (TL32711), a Small Molecule Smac Mimetic, Induces Regressions in Childhood Acute Lymphoblastic Leukemia (ALL) Xenografts That Express TNFα and Synergizes with TNFα in Vitro – A Report From the Pediatric Preclinical Testing Program (PPTP)". Blood 120, № 21 (16 листопада 2012): 3565. http://dx.doi.org/10.1182/blood.v120.21.3565.3565.
Повний текст джерелаWang, Beatrice T., Melanie Desbois, Susan E. Calhoun, Thomas J. Matthew, Poonam Yakkundi, Ling Wang, Xingjie Chen, et al. "Abstract 1068: Anti-DR5 agonist IgM antibody IGM-8444 combined with SMAC mimetic birinapant induces strong synergistic tumor cytotoxicity." Cancer Research 82, no. 12_Supplement (June 15, 2022): 1068. http://dx.doi.org/10.1158/1538-7445.am2022-1068.
Повний текст джерелаJoshi, Indira D., and Mitchell R. Smith. "Birinapant Enhances Bendamustine-Induced Apoptosis In Activated B Cell-Diffuse Large Cell Lymphoma Cells." Blood 122, no. 21 (November 15, 2013): 5150. http://dx.doi.org/10.1182/blood.v122.21.5150.5150.
Повний текст джерелаMorrish, Emma, Liana Mackiewicz, Natasha Silke, Marc Pellegrini, John Silke, Gabriela Brumatti, and Gregor Ebert. "Combinatorial Treatment of Birinapant and Zosuquidar Enhances Effective Control of HBV Replication In Vivo." Viruses 12, no. 8 (August 17, 2020): 901. http://dx.doi.org/10.3390/v12080901.
Повний текст джерелаMorrish, Emma, Anthony Copeland, Donia M. Moujalled, Jason A. Powell, Natasha Silke, Ann Lin, Kate E. Jarman, et al. "Clinical MDR1 inhibitors enhance Smac-mimetic bioavailability to kill murine LSCs and improve survival in AML models." Blood Advances 4, no. 20 (October 20, 2020): 5062–77. http://dx.doi.org/10.1182/bloodadvances.2020001576.
Повний текст джерелаSchilder, Russell J., Mark Albertella, James Fredric Strauss, Malin Sydvander, Dung T. Le, Stefan Norin, Monica M. Mita, et al. "Determination of the recommended phase II dose of birinapant in combination with pembrolizumab: Results from the dose-escalation phase of BPT-201." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): 2506. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.2506.
Повний текст джерелаLalaoui, Najoua, Delphine Merino, Goknur Giner, François Vaillant, Diep Chau, Lin Liu, Tobias Kratina, et al. "Targeting triple-negative breast cancers with the Smac-mimetic birinapant." Cell Death & Differentiation 27, no. 10 (April 27, 2020): 2768–80. http://dx.doi.org/10.1038/s41418-020-0541-0.
Повний текст джерелаДисертації з теми "Birinapant"
Zhu, Xu. "Pharmacokinetic and Pharmacodynamic Analysis of Gemcitabine and Birinapant Combinations in Pancreatic Cancer." Thesis, State University of New York at Buffalo, 2017. http://pqdtopen.proquest.com/#viewpdf?dispub=10263448.
Повний текст джерелаPancreatic cancer is the one of the leading causes of cancer-related deaths in the United States and is characterized with low survival rate and high drug resistance. Because of the redundant and highly mutated signaling pathways in pancreatic cancer, numerous combinational therapies have been sought. Currently the selection of drug combinations is largely empirical and methods of evaluating and optimizing drug combinations have not been standardized. An important reason for this is the lack of comprehensive characterization of drug mechanisms of action and causes for drug resistance.
The purposes of this dissertation are: first, to set up a paradigm for evaluating drug combinations mathematically and translating the evaluation methods from in vitro to in vivo preclinical systems; second, to serve as an example for characterizing the biological signaling pathways and drug pharmacology comprehensively with systems modeling approaches, supported with “big data” from advanced techniques such as proteomic analysis; and third, using such systems models, further selecting and optimizing drug combinations to reverse drug resistance and enhance efficacy.
The two drugs selected are gemcitabine, a major component in the therapies for pancreatic cancer treatment, and birinapant, an antagonist of inhibitor of apoptosis proteins (IAP). In Chapter 1, the efficacy of this drug combination was evaluated in PANC-1 cells. A basic pharmacodynamic (PD) model was developed to characterize the temporal changes in the numbers of attached and floating cells after treatments, and synergistic effects were observed for both proliferation inhibition and death induction. Measurements of cell cycle distributions and apoptosis were then obtained and a mechanism-based PD model was developed to reveal more details and capture the major features of the beneficial interactions. From the mechanism-based PD model, different exposure schedules were tested and an optimal one to achieve maximal efficacy was proposed.
Assumptions were made in developing the mechanism-based PD model in Chapter 1. In Chapter 2, a proteomic approach was utilized for a comprehensive, unbiased study of proteins perturbed by gemcitabine and birinapant to test previous hypotheses. The mechanisms of action for both drugs were characterized more intensively, and additional details were incorporated into the interaction knowledge described previously. Based on the proteomics data, reasons for gemcitabine resistance were discussed, and regulators of DNA damage responses involving DNA repair, anti-apoptosis, and pro-migration and invasion proteins were proposed as promising candidates for therapeutic targeting.
With the rich quantitative proteomics data, a network modeling approach was attempted in Chapter 3. Quantitative relationships were developed for selected signaling pathways of cell cycle regulation, DNA damage responses, DNA repair, apoptosis, NF-κB, and MAPK-p38, which were then linked to describe the cell cycle progression and apoptosis, and finally to changes in cell numbers. Based on the developed network model, simulations were made under different conditions and compared with observations, serving as a validation process. The impact of p53 mutation and p53 silencing on the efficacy of gemcitabine was tested with this model. Sobol Sensitivity Analysis was applied to select promising targets to be combined with gemcitabine. In addition, the efficacy of curcumin combined with gemcitabine was evaluated based on the model simulation.
With extensive evaluation and comprehensive characterization of the mechanisms of this drug combination in cell culture, efforts were continued to investigate the effects of the combination in a mice xenograft model. In Chapter 4, pharmacokinetic information for gemcitabine and birinapant was gathered from the literature and full physiologically-based pharmacokinetic models (PBPK) were developed to characterize drug distribution in the body and into the pancreatic tumor. The tumor concentrations then were used to drive inhibition in tumor growth and a semi-mechanistic PBPK/PD model was developed to evaluate the efficacy of the drug combination in vivo. Their joint effects were revealed as merely additive. The network model developed in Chapter 3 was introduced to bridge the PBPK and PD models, and reasons for the discrepancies in vitro and in vivo were explored. Model predictions showed that simultaneous dosing was preferable to sequential dosing in vivo with stronger suppression of the DNA repair signaling.
In summary, this dissertation proposed a paradigm for evaluating drug combinations quantitatively in preclinical systems of cell lines and xenograft models. Comprehensive characterization of drug mechanisms of action and biological systems through network modeling can facilitate the selection and optimization of candidates for anti-cancer combination therapy. The bridging of knowledge in different scales with mathematical models in different complexity helps to minimize the gap of translating from in vitro to in vivo or even from preclinical to clinical research.
Schüßler, Lion Maximilian [Verfasser], and Urs [Gutachter] Müller-Richter. "Analyse der Wirksamkeit der SMAC Mimetics Birinapant, BV6 und LCL161 und der Zytostatika Docetaxel und Paclitaxel auf Zellen des Multiplen Myeloms / Lion Maximilian Schüßler ; Gutachter: Urs Müller-Richter." Würzburg : Universität Würzburg, 2020. http://d-nb.info/1215033931/34.
Повний текст джерелаSchüßler, Lion Maximilian. "Analyse der Wirksamkeit der SMAC Mimetics Birinapant, BV6 und LCL161 und der Zytostatika Docetaxel und Paclitaxel auf Zellen des Multiplen Myeloms." Doctoral thesis, 2020. https://nbn-resolving.org/urn:nbn:de:bvb:20-opus-208974.
Повний текст джерелаIn multiple myeloma malignant plasma cells show a high level of clonal heterogeneity which leads to resistance to current medication and furthermore bad prognosis of treatment. New developed substances like Smac Mimetics Birinapant, BV6 and LCL161 shall induce apoptosis in multiple myeloma cells in imitating of the cellular protein SMAC/Diablo which is an antagonist of apoptosis inhibitors. This study investigates the in vitro effectiviness of the SMAC Mimetics Birinapant, BV6 and LCL161 and of the cytostatics Docetaxel and Paclitaxel on 10 human multiple myeloma cells. Some celllines showed in a combination treatement with Smac Mimetics and zytostatics a synergetic effect on cell viability and an overcoming of drug resistance. Further studies shall investigate the benefits and clinical use of combination treatment with Smac Mimetics for patients with recurrent and refractory multiple myeloma
Тези доповідей конференцій з теми "Birinapant"
Papaevangelou, Efthymia, Gilberto S. Almeida, Yann Jamin, Simon P. Robinson, and Nandita M. deSouza. "Abstract 2930: Differential tumour response to birinapant and irinotecan revealed by non-invasive MRI." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-2930.
Повний текст джерелаNeiman, Eric M., Christopher A. Benetatos, Gurpreet S. Kapoor, Yasuhiro Mitsuuchi, Mark A. McKinlay, Martin E. Seipel, Guangyao Yu, Stephen M. Condon, and Srinivas K. Chunduru. "Abstract 5302: Characterization of tumor cell lines resistant to birinapant, a novel bivalent smac mimetic." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-5302.
Повний текст джерелаLa, Vincent, Rachel Fujikawa, Deanna Janzen, Liat Bainvoll, and Sanaz Memarzadeh. "Abstract LB-131: Birinapant and carboplatin co-therapy can effectively target platinum resistant ovarian cancer initiating cells." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-lb-131.
Повний текст джерелаDerakhshan, Adeeb, Danielle Eytan, Grace Snow, Sophie Carlson, Anthony Saleh, Hui Cheng, Stephen Schiltz, et al. "Abstract 3821: Targeted therapy for head and neck squamous cell carcinoma using the novel SMAC-mimetic birinapant." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-3821.
Повний текст джерелаFichtner, Michael, Emir Bozkurt, Katherine McAllister, Christopher McCann, Daniel Longley, and Jochen H. Prehn. "Abstract 3907: Birinapant co-treatments of colon cancer cell lines show consensus molecular subtype-specific synergistic effects." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-3907.
Повний текст джерелаKapoor, Gurpreet Singh, Christopher A. Benetatos, Yasuhiro Mitsuuchi, Eric M. Neiman, Guangyao Yu, Mark A. Mckinlay, Jennifer Burns, John Silke, Stephen M. Condon, and Srinivas K. Chunduru. "Abstract 2278: The SMAC-mimetic birinapant regulates autocrine TNF production by caspase-8:RIPK1 complex via p38MAPK pathway." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-2278.
Повний текст джерелаBenetatos, Christopher A., Jennifer M. Burns, Ernest C. Borden, Daniel Lindner, Yasuhiro Mitsuuchi, Mark A. Mckinlay, Gurpreet Singh Kapoor, et al. "Abstract 3336: The Smac Mimetic Birinapant Synergistically Induces Apoptosis in Combination with Type I Interferons and GM-CSF." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-3336.
Повний текст джерелаXie, Xuemei, Jangsoon Lee, Troy Pearson, Alexander Y. Lu, Debu Tripathy, Gayathri R. Devi, Chandra Bartholomeusz, and Naoto T. Ueno. "Abstract 548: Birinapant enhances gemcitabine's anti-tumor efficacy in triple-negative breast cancer by inducing intrinsic pathway-dependent apoptosis." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-548.
Повний текст джерелаRichmond, Jennifer, Kathryn Evans, Alissa Robbins, Raushan T. Kurmasheva, Peter J. Houghton, Malcolm A. Smith, and Richard B. Lock. "Abstract 1620: In vivo and in vitro efficacy of birinapant in preclinical models of Ph-like pediatric acute lymphoblastic leukemia." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-1620.
Повний текст джерелаAn, Yi, Jun W. Jeon, Lillian Sun, Adeeb Derakhshan, Jianhong Chen, Hui Cheng, Xinping Yang, Christopher Silvin, Carter Van Waes, and Zhong Chen. "Abstract 5175: Birinapant enhances death agonist antibody against TRAILR2 anti-tumor activity in HPV-positive head and neck squamous cell carcinomas." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-5175.
Повний текст джерела